Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

LIMS Training in Pharma: How Role-Based LabWare Training Reduced Deviations and Improved User Competency

A new specification, material code, or product version may look like a simple LIMS update. However, these changes can affect specifications, calculations, batch release, shelf life, and data integrity.

In this LabWare 8 project, extensive master data existed across tests, specifications, products, materials, sample templates, limits, and units. Yet there was no consistent process for initiating, documenting, approving, or controlling changes.

Business users wanted flexibility. Meanwhile, QA and CSV teams needed traceability and risk-based control.

The project therefore needed a practical way to keep LIMS master data both agile and compliant.

Our team introduced risk-based master data categories and defined tailored change paths based on their GMP impact.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • No Clear Change Process: Teams lacked a consistent method for initiating, assessing, approving, and documenting LIMS master data changes.
  • Unclear Master Data Risk Levels: There was no shared distinction between low-risk information and data affecting product quality, batch release, or patient safety.
  • Inconsistent Change Control: Some changes triggered extensive Change Control, while others were handled informally.
  • Conflicting Stakeholder Needs: Business users wanted speed, while QA and CSV required control, traceability, and risk management.
  • Weak Inspection Justification: Teams could not easily explain why one master data change required formal Change Control while another did not.
  • Potential GMP and Data Integrity Impact: Incorrect specifications, limits, units, tests, or calculation rules could affect routine data and quality decisions.

Zamann Pharma Support’s Approach

  • Catalogue Master Data: We listed LabWare master data, including products, specifications, tests, materials, limits, units, workflows, and reference values.
  • Group Data Into Categories: We organized the master data into logical groups such as product data, specifications, analytical methods, calculations, and reference lists.
  • Perform Risk Assessment: Each category was assessed for potential effects on product quality, patient safety, batch release, shelf life, data integrity, and regulatory reporting.
  • Assign Risk Levels: Master data was classified as low, medium, or high risk according to its potential GMP impact.
  • Define Risk-Based Change Paths: Low-risk changes used a documented request process. Medium- and high-risk changes required dedicated Master Data Change Control.
  • Tailor Master Data Change Control: The process included risk assessment, impact assessment, regression testing, and appropriate QA or regulatory approvals.
  • Create a Risk & Change Matrix: A living matrix documented each master data category, its risk level, and the required change path.
  •  Strengthen Traceability: Where possible, LabWare supported audit trails, object versioning, and reporting of who changed critical data and when.
  • Train Users by Role: Training explained master data risks and gave deeper guidance to master data stewards, QA approvers, and LIMS administrators.

Results Achieved

  • Clearer Change Decisions: The Master Data Risk & Change Matrix gave users a consistent way to select the correct change process.
  • Faster Low-Risk Changes: Low-risk changes could follow a lean documented workflow without formal Change Control.
  • Stronger Control of Critical Data: Medium- and high-risk changes received defined risk, impact, testing, and approval controls.
  • More Consistent GMP Justification: Documented risk categories helped teams explain why different changes required different controls.
  • Improved Traceability: Audit trails, versioning, and change records supported clearer master data history.
  • Better Inspection Readiness: Teams could explain how master data was categorized, assessed, changed, approved, and documented.
  • Balance Between Agility and Control: Critical changes received stronger governance, while lower-risk updates remained efficient.
Laboratory
Pharmaceutical professionals participating in GMP training session focused on quality systems, inspection readiness, and compliance within regulated environments
Services

GMP-Trainings and Quality Coaching

Through hands-on training and coaching, we help pharmaceutical professionals build practical GMP skills, strengthen quality mindset, and develop effective collaboration within regulated environments.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. When does a LabWare LIMS master data change require formal Change Control?

Formal Change Control applies to medium- and high-risk master data under the approach described in this case. Examples include product versions, specifications, shelf life, critical limits, calculation rules, and test definitions.

These changes use a dedicated Master Data Change Control that defines risk, impact, regression testing, and required approvals. By contrast, low-risk changes can use a documented ticket or request without formal Change Control.

2. How can GMP teams classify LIMS master data using an ICH Q9 risk-based approach?

Teams can assess each master data category against its potential effect on quality and safety. The case considered whether incorrect data could affect product quality, patient safety, batch release, shelf life, potency, data integrity, regulatory reporting, or trend interpretation. Based on that assessment, master data was classified as low, medium, or high risk.

3. What LIMS master data evidence should be available during a GMP inspection?

The case highlights several types of evidence. Teams should be able to explain how specifications and product data are controlled. They should also identify who can change tests or limits and show the history of critical changes. In addition, the approach uses documented risk categories, defined change paths, audit trails, and records showing what changed, who changed it, and why.